SG11201407345QA - Pyrazole compounds as sglt1 inhibitors - Google Patents
Pyrazole compounds as sglt1 inhibitorsInfo
- Publication number
- SG11201407345QA SG11201407345QA SG11201407345QA SG11201407345QA SG11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- indiana
- indianapolis
- iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/169546 A1 (51) International Patent Classification: C07D 471/10 (2006.01) A61K31/438 (2006.01) C07D 487/10 (2006.01) A61P 3/10 (2006.01) A61K31/4155 (2006.01) (21) International Application Number: PCT/US2013/039164 (22) International Filing Date: 2 May 2013 (02.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/645,101 10 May 2012 (10.05.2012) US 61/769,221 26 February 2013 (26.02.2013) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: QU, Fucheng; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). MANTLO, Nathan Bryan; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agents: LENTZ, Nelsen L. et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, [Continued on next page] (54) Title: PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS Formula II (57) Abstract: The present invention provides a compound of Formula (II): wherein X represents the following: or a pharmaceutically acceptable salt thereof. WO 2013/169546 A11 lllll llllllll II llllll III lllll lllll III III III lllll lllll lllll lllll llll llll lllll lllllll llll llll UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261645101P | 2012-05-10 | 2012-05-10 | |
| US201361769221P | 2013-02-26 | 2013-02-26 | |
| PCT/US2013/039164 WO2013169546A1 (en) | 2012-05-10 | 2013-05-02 | Pyrazole compounds as sglt1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407345QA true SG11201407345QA (en) | 2014-12-30 |
Family
ID=48428684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407345QA SG11201407345QA (en) | 2012-05-10 | 2013-05-02 | Pyrazole compounds as sglt1 inhibitors |
Country Status (43)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113086C2 (en) * | 2012-05-10 | 2016-12-12 | PRAZOLE COMPOUNDS AS SGLT1 INHIBITORS | |
| TW201425326A (en) | 2012-10-05 | 2014-07-01 | Lilly Co Eli | Novel urea compounds |
| AR097890A1 (en) | 2013-10-17 | 2016-04-20 | Lilly Co Eli | UREA COMPOUNDS |
| JO3298B1 (en) | 2013-11-01 | 2018-09-16 | Lilly Co Eli | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors |
| AR098670A1 (en) * | 2013-11-08 | 2016-06-08 | Lilly Co Eli | SGLT1 INHIBITOR |
| CN110054657B (en) * | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | Glucopyranosyl substituted pyrazole compound and preparation method thereof |
| AU2019249560B2 (en) * | 2018-04-04 | 2023-10-05 | Japan Tobacco Inc. | Heteroaryl-substituted pyrazole compound and medicinal use thereof |
| AU2020341926A1 (en) * | 2019-09-04 | 2022-03-17 | Japan Tobacco Inc. | Therapeutic or prophylactic method for diabetes using combination medicine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382480C (en) | 1999-08-31 | 2008-09-30 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US7087579B2 (en) | 2001-02-26 | 2006-08-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| EP1400529A4 (en) | 2001-05-30 | 2007-12-19 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| CA2494179C (en) * | 2002-08-08 | 2012-04-24 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| JP2004137245A (en) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | Pyrazole derivative, pharmaceutical composition containing the same, its pharmaceutical use and production intermediate |
| DE102004028241B4 (en) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | New fluoroglycoside derivatives of pyrazoles, medicines containing these compounds and manufacture of these medicines |
| NZ573687A (en) * | 2006-05-19 | 2010-10-29 | Taisho Pharmaceutical Co Ltd | C-phenyl glycitol compound for the treatment of diabetes |
| US8399418B2 (en) | 2007-12-27 | 2013-03-19 | Kissei Pharmaceutical Co., Ltd. | Monosebacate of pyrazole derivative |
| US8466113B2 (en) | 2009-02-23 | 2013-06-18 | Taisho Pharmaceutical Co., Ltd. | 4-isopropylphenyl glucitol compounds as SGLT1 inhibitors |
| RU2012117560A (en) | 2009-10-02 | 2013-11-10 | Санофи | USE OF COMPOUNDS WITH ACTIVITY OF INHIBITORS SGLT-1 / SGLT-2 FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF BONE DISEASES |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| UA113086C2 (en) * | 2012-05-10 | 2016-12-12 | PRAZOLE COMPOUNDS AS SGLT1 INHIBITORS |
-
2013
- 2013-02-05 UA UAA201412088A patent/UA113086C2/en unknown
- 2013-04-23 JO JOP/2013/0117A patent/JO3136B1/en active
- 2013-04-23 AR ARP130101348A patent/AR090806A1/en active IP Right Grant
- 2013-04-25 TW TW102114877A patent/TWI579295B/en active
- 2013-05-02 CA CA2869323A patent/CA2869323C/en active Active
- 2013-05-02 JP JP2015511518A patent/JP6148725B2/en active Active
- 2013-05-02 US US13/875,314 patent/US8697849B2/en active Active
- 2013-05-02 PE PE2014001716A patent/PE20142399A1/en active IP Right Grant
- 2013-05-02 DK DK13722231.1T patent/DK2850084T3/en active
- 2013-05-02 AP AP2014008044A patent/AP3593A/en active
- 2013-05-02 PT PT137222311T patent/PT2850084T/en unknown
- 2013-05-02 ES ES13722231.1T patent/ES2588835T3/en active Active
- 2013-05-02 MY MYPI2014703279A patent/MY177326A/en unknown
- 2013-05-02 MX MX2014013615A patent/MX357058B/en active IP Right Grant
- 2013-05-02 SI SI201330209A patent/SI2850084T1/en unknown
- 2013-05-02 IN IN7996DEN2014 patent/IN2014DN07996A/en unknown
- 2013-05-02 SG SG11201407345QA patent/SG11201407345QA/en unknown
- 2013-05-02 AU AU2013259946A patent/AU2013259946B2/en active Active
- 2013-05-02 ME MEP-2016-121A patent/ME02405B/en unknown
- 2013-05-02 EP EP13722231.1A patent/EP2850084B1/en active Active
- 2013-05-02 EA EA201491852A patent/EA024207B1/en not_active IP Right Cessation
- 2013-05-02 RS RS20160626A patent/RS55107B1/en unknown
- 2013-05-02 HU HUE13722231A patent/HUE030414T2/en unknown
- 2013-05-02 BR BR112014026198-9A patent/BR112014026198B1/en active IP Right Grant
- 2013-05-02 NZ NZ700356A patent/NZ700356A/en unknown
- 2013-05-02 WO PCT/US2013/039164 patent/WO2013169546A1/en active Application Filing
- 2013-05-02 KR KR1020147031119A patent/KR101685779B1/en active IP Right Grant
- 2013-05-02 LT LTEP13722231.1T patent/LT2850084T/en unknown
- 2013-05-02 PL PL13722231T patent/PL2850084T3/en unknown
-
2014
- 2014-02-18 US US14/182,354 patent/US9296775B2/en active Active
- 2014-09-30 TN TNP2014000410A patent/TN2014000410A1/en unknown
- 2014-10-10 CR CR20140473A patent/CR20140473A/en unknown
- 2014-10-16 ZA ZA2014/07531A patent/ZA201407531B/en unknown
- 2014-10-22 CL CL2014002845A patent/CL2014002845A1/en unknown
- 2014-10-30 IL IL235427A patent/IL235427A/en active IP Right Grant
- 2014-11-03 DO DO2014000250A patent/DOP2014000250A/en unknown
- 2014-11-05 MA MA37501A patent/MA37501B1/en unknown
- 2014-11-05 GT GT201400242A patent/GT201400242A/en unknown
- 2014-11-07 EC ECIEPI201426088A patent/ECSP14026088A/en unknown
- 2014-11-07 PH PH12014502492A patent/PH12014502492B1/en unknown
- 2014-11-11 CO CO14249415A patent/CO7141429A2/en unknown
-
2015
- 2015-03-26 HK HK15103083.5A patent/HK1202542A1/en unknown
-
2016
- 2016-07-06 HR HRP20160804TT patent/HRP20160804T1/en unknown
- 2016-08-11 CY CY20161100801T patent/CY1117912T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201408629QA (en) | Dimethyl-benzoic acid compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201407189XA (en) | C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201810177VA (en) | Pet-imaging immunomodulators | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201808686VA (en) | Synthesis of indazoles |